MARKET

GNFT

GNFT

GENFIT S.A.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.55
+0.55
+3.93%
After Hours: 14.55 0 0.00% 16:00 10/14 EDT
OPEN
14.80
PREV CLOSE
14.00
HIGH
14.80
LOW
14.30
VOLUME
24.06K
TURNOVER
--
52 WEEK HIGH
26.25
52 WEEK LOW
13.21
MARKET CAP
526.48M
P/E (TTM)
-4.2771
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of GNFT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

GNFT News

  • 89bio Files Initial Registration Statement For U.S. IPO
  • Seeking Alpha - Article.7h ago
  • The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug
  • Benzinga.5d ago
  • 9 Healthcare Stocks Moving In Tuesday's Pre-Market Session
  • Benzinga.6d ago
  • The Daily Biotech Pulse: D-Day For Clinuvel, Qiagen Warns Of Q3 Shortfall, Prevail Announces Gene Therapy Collaboration
  • Benzinga.6d ago

More

Industry

Biotechnology & Medical Research
+0.42%
Pharmaceuticals & Medical Research
+0.09%

Hot Stocks

Name
Price
%Change

About GNFT

Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
More

Webull offers Genfit SA (GNFT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.